RECOMBINANT ADAMTS13 (rADAMTS13), -, RITUXIMAB clinical trials

A Phase 2b, multicenter, randomized, double-blind study of safety and efficacy of TAK-755 (rADAMTS13) with minimal to no plasma exchange (PEX) in the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP)

This study looks at a new medicine, TAK-755, for a rare blood condition called iTTP. It aims to see if TAK-755 is safe and effective when used with less or no plasma exchange, which is a common treatment for iTTP.